ROCKVILLE, Md., Nov. 30, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that Jeffrey Riley, CEO, will present at the Fifth Annual LD MICRO Conference on Thursday, December 6, 2012 at 9:00 a.m. (PT). The conference will be held December 5-6, 2012 at the Luxe Sunset Bel Air Hotel in Los Angeles, California. Synthetic Biologics’ management will be available during the conference for one-on-one meetings. Please contact LD MICRO to schedule a meeting.
A live webcast of Synthetic Biologics’ presentation can be accessed by logging onto the internet at http://wsw.com/webcast/ldmicro3/syn/. After the presentation, a replay will be archived and accessible for 30 days at the same website.
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the development of product candidates for serious infections and diseases. Synthetic Biologics is developing a biologic for the prevention of C. diff infection, and a series of monoclonal antibodies (mAbs) for the treatment of serious infectious diseases, including Acinetobacter. The Company is also developing a synthetic DNA-based therapy for the treatment of pulmonary arterial hypertension (PAH). In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and designing a clinical development pathway for the treatment of amyotrophic lateral sclerosis (ALS). For more information, please visit Synthetic Biologics’ website at www.therivabio.com.
SOURCE Synthetic Biologics, Inc.
Released November 30, 2012